TEM1 Polyclonal Antibody for FC, IHC, WB, ELISA
Cat no : 18160-1-AP
CD164L1, CD248, CD248 molecule, endosialin, Endosialin, TEM1, Tumor endothelial marker 1
|Positive WB detected in||HeLa cells, A375 cells, COLO 320 cells, HEK-293 cells, mouse colon tissue, mouse heart tissue, mouse stomach tissue, NIH/3T3 cells, SH-SY5Y cells|
|Positive IHC detected in||human lung cancer tissue, human renal cell carcinoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
18160-1-AP targets TEM1 in FC, IHC, WB, ELISA applications and shows reactivity with human, mouse, rat samples.
|Reactivity||human, mouse, rat|
|Cited Species||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||TEM1 fusion protein Ag12990|
|Full Name||CD248 molecule, endosialin|
|Calculated molecular weight||757aa,81 kDa|
|Observed molecular weight||81 kDa|
|GenBank accession number||BC051340|
|Gene ID (NCBI)||57124|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20oC. Aliquoting is unnecessary for -20oC storage.|
TEM1 (Tumor endothelial marker 1), also named as CD248, Endosialin and CD164L1, is a C-type lectin-like domain (CTLD) containing type I transmembrane glycoprotein. It is now considered to be a highly selective marker for activated perivascular and stromal cells, detected in most cancers and at least some inflammatory disorders. CD248 plays a role in tumor angiogenesis. It is a potential diagnostic tool and therapeutic target of inflammatory and malignant disease. Two isoforms of human TEM1 exist. The calculated molecular weights of the two isoforms are 81 kDa and 46 kDa, respectively. Native TEM1 can be glycosylated, and the glycosylated form has a larger apparent molecular weight than 81 kDa.
TGFbeta-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells.
Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells.
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.
Specific loss of adipocyte CD248 improves metabolic health via reduced white adipose tissue hypoxia, fibrosis and inflammation.